Novo Nordisk, the manufacturer of Wegovy, responded strongly to the initial launch of Hims & Hers’ compounded semaglutide ...

In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate ...

Eli Lilly reinforced its push into next-generation immunology and oncology innovation through two major transactions: the planned acquisition of Orna Therapeutics and a new large-scale strategic ...

Yerem Yeghiazarians founder and CEO of Soley Therapetuics touches on how Soley's approach reverses traditional drug development and reduces failure risks.

Real-world data (RWD) is transforming clinical research, augmenting existing randomized controlled trial (RCT) data to de-risk studies and improve generalizability. With regulators setting clearer ...

After months of speculation, TrumpRx is live and offering Americans a variety of important medications at most-favored-nation ...

In his post, Makary said, “FDA will take swift action against companies’ mass-marketing illegal copycat drugs, claiming they ...

FDA has approved Vybrique, the first oral film formulation of sildenafil for the treatment of erectile dysfunction, offering ...

SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...

In a lean biotech environment with aggressive milestones, teams often accept reporting that is “good enough.” But those ...

In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...

Eli Lilly is investing $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania, to produce injectable ...